BeOne Medicines Ltd. concluded a statutory tax audit in China, resulting in a settlement agreement with local tax authorities to make an income tax payment of approximately RMB 446 million. This payment, which includes surcharges and related interest, is expected to be recognized in the second quarter of fiscal 2026 financial statements. BeOne Medicines Ltd. is a pharmaceutical company focused on developing medicines for various therapeutic areas.

At its June 11, 2026, Annual General Meeting, BeOne Medicines Ltd. shareholders approved several key proposals, including the Fifth Amended and Restated 2016 Share Option and Incentive Plan, which increases authorized shares for issuance by 75,400,000 ordinary shares. Shareholders also approved the Sixth Amended and Restated 2018 Employee Share Purchase Plan, increasing the maximum ordinary shares available for sale by 3,250,000. Additionally, the meeting resulted in the election of several directors, the ratification of Ernst & Young LLP as independent auditors, and the approval of general mandates for issuing and repurchasing shares. Four directors, including Michael Goller and Ranjeev Krishana, departed as they did not stand for re-election. BeOne Medicines Ltd. is a biotechnology company focused on medicinal development.